P53 Ki67在三阴乳腺癌中的表达及意义
被引量:3
摘要
乳腺癌是全球范围内女性最常见的恶性肿瘤,并且其发病率还在以每年2%的速度递增,且呈年轻化趋势。三阴乳腺癌是指雌激素受体(E R )、孕激素受体(PR)及人表皮生长因子受体(Her-2)均为阴性的乳腺癌,约占乳腺癌的10%~17%。这一类乳腺癌具有高度侵袭性,患者复发率高,5年生存率低,对内分泌治疗不敏感。本研究利用免疫组织化学法对128例三阴乳腺癌及168例非三阴乳腺癌组织中 P53及Ki67的表达进行比较,现报告如下。
出处
《山西医药杂志》
CAS
2014年第6期632-633,共2页
Shanxi Medical Journal
参考文献9
-
1Nielsen TO, Hsu FD, Jensen K, et al. Advantage and the in- cidence of the basalcarcinoma[J]. Clin Cancer Res, 2006, 10 (2) 5367-5374.
-
2Dent R,Trudeau M,Pritchard KJ,et al. Triple negative breast cancer: clinical features and patterns of recurrence[J]. Clin Cancer Res, 2007,13 (5) : 4429-4434.
-
3Perou CM, Sorlic T, Eisen MB, et al. Molecular portraits of human breast cancer[J]. Nature, 2000,406(6797) :747-752.
-
4Iwamb P,Crawford L. Charaeterization of the human p53 gene [J]. Molcell Bio1,1986,6(5) :1379-1385.
-
5Bidard FC, Matthieu MC, Chollet P, et ai. p53 status and ef- ficacy of primary anthracyelines/alkylating agent-based regi- men according to breast cancer molecular classes[J]. Ann On- col,2008, 19(7) 1261-1265.
-
6Menezes MV, Cestari AL, Almeida O, et al. Protein expres- sion of Cerb-2 and p53 in normal ducts,ductal carcinoma in situ and invasive carcinoma of the same breast[J]. Sao Paulo Med J, 2006,124(3) : 121-124.
-
7Gerdes J, Schwab U, Lemke H, et al. Production of a mouse monoclonal antibody reactive with a human nuclear antigen as- sociated with cell proliferation[J]. Int J Cancer, 1983,31 (1) . 13.
-
8邓秀娟,吴海根.Ki67、PTEN在卵巢浆液性肿瘤中的表达及临床意义[J].实用癌症杂志,2011,26(4):365-367. 被引量:15
-
9祝玉祥,章佳新,邵稳喜,何春兰,诸林海,符德元.ki67在三阴性乳腺癌组织中的表达及意义[J].中国现代普通外科进展,2010,13(9):679-680. 被引量:12
二级参考文献15
-
1邵汇琳,沈丹华,薛卫成,李艺,虞有智.卵巢上皮性肿瘤的临床病理特征及其细胞周期素D1和p53蛋白表达的研究[J].中华妇产科杂志,2007,42(4):227-232. 被引量:10
-
2Tan PH,Bay BH,Yip G,et al.Immunohistochemical detection of ki67in breast cancer correlates with transcriptional regulation of genes related to apoptasis and cell death[J].Mod Pathol,2005,18(3):374-381.
-
3Nielsen TO,Hsu FD,Jensen K,et al.Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma[J].Clin Cancer Res,2004,10(2):5367-5374.
-
4Siziopkou KP,Cobleigh M.The basal subtype of breast carcinomas may represent the group of breast tumors that could benefit from EGFR-targeted therapies[J].Breast,2007,16(1):104-107.
-
5Dent R,Trudeau M,Pritchard KJ,et al.Triple negative breast cancer:clinical features and patterns of recurrence[J].Clin Cancer Res,2007,13(5):4429-4434.
-
6Sorlie T,Perou CM,Tibshirani R,et al.Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications[J].Proc Natl Acad Sci USA,2001,98(6):10869-10874.
-
7ivasy CA,Karaca G,Nanda R,et al.Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma[J[.Mod Pathol,2006,19(2):264-271.
-
8Rakha EA,EI-Sayed ME,Green AR,et al.Prognostic markers in triple negative breast cancer[J].Cancer,2006,109(1):25-32.
-
9Haffty BG,Yang Q,Reiss M,et al.Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer[J].J Clin Oncol,2006,24(6):5652-:5657.
-
10Bhataydekar JM,Patel DD,Shah NG,et al.Prognostic significance of immunohisto-chemically localized biomarkers in stage Ⅱ and stageⅢ breast cancer,a multivariate analysis[J].Ann Surg Oncol,2000,7(4):305-311.
共引文献24
-
1沈三弟,陈卓荣,黄湛,肖高芳,雷睿文.Ki67在不同分子类型乳腺癌组织中的表达及意义[J].实用癌症杂志,2012,27(3):247-249. 被引量:13
-
2张晓兰,王水,郑琳.三阴性乳腺癌82例临床特征与预后分析[J].实用临床医药杂志,2012,16(15):142-144. 被引量:3
-
3李林株,郭灵敏,贺青蓉.阴道镜下多点活检组织中PTEN和ki-67表达及其对宫颈癌早期诊断的意义[J].国际医药卫生导报,2013,19(1):36-38.
-
4董欢,林燕苹,应学翔,何萍青.Ki67、增殖细胞核抗原在不同分子分型乳腺癌组织中的表达及意义[J].中华乳腺病杂志(电子版),2013,7(2):15-20. 被引量:12
-
5黄柏丽,郦秀芳.阴道镜下多点活检结合PTEN和ki-67表达在宫颈癌早期诊断中的意义[J].中国内镜杂志,2013,19(5):476-479. 被引量:11
-
6刘莉萍,孙凤玲,魏亚,潘慧,白君,李维,戚晓东,周慧颖.表皮生长因子受体、p53、Ki-67在三阴性乳腺癌中的表达及其意义[J].肿瘤研究与临床,2013,25(10):669-671. 被引量:8
-
7刘秦香,李丽.Ki-67在不同类型乳腺癌中的研究进展[J].现代医药卫生,2014,30(3):379-381. 被引量:2
-
8况丽平,沈金辉,王少洪.三阴性乳腺癌的临床病理特征及TopoⅡα、Ki67表达[J].国际医药卫生导报,2014,20(3):325-328. 被引量:2
-
9吴骥,管小青,顾书成,郑向欣,侍孝红,江小玲,袁牧,张旭旭.乳腺浸润性导管癌组织中COX-2和Ki-67的表达及相关性分析[J].中国普外基础与临床杂志,2014,21(2):197-201. 被引量:6
-
10马会清,杨秀凤,程海燕.宫颈鳞癌中基质细胞衍生因子-1、CXC趋化因子受体4、基质金属蛋白酶-2和Ki-67的表达及意义[J].中华妇幼临床医学杂志(电子版),2014,10(2):74-78. 被引量:7
同被引文献24
-
1工斐,余之刚.乳腺癌预防和筛查新进展[J].临床普外科电子杂志,2013,1(1):57-61. 被引量:7
-
2Pilati P, Nitti D, Mocellin S. Cancer resistance to type II topoisomerase inhibitors[ J ]. Curr M ed Chem,2012, 19 (23) : 3900 - 3906.
-
3Harem C,EI- Masri M,Poliquin G, et al. A single- centre chart review exploring the adjusted association between breast cancer phenotype and prognosis [ J ]. Curr Oncol,2011,18(4) :191 -196.
-
4Lara - Medina F, Parez - Sanchez V, et al. Triple - negative breast cancer in Hispanic patients:high prev- alence, poor prognosis, and association with menopaus- al status, body mass index, and parity [ J ]. Cancer, 2011,117(16) :3658 -3669.
-
5Lee JA,Kim KI. Triple negative breast cancer in korea- distinct biology with different impact of prognostic fac- tors on survival [ J ]. Breast Cancer Treat, 2010, 123 (1) :177 -187.
-
6Chae B J, Bae JS, Lee A. P53 as a specific prognostic factor in triple- negative breast cancer[ J]. Clin On- col,2009,39:217 - 224.
-
7Reiki Nishimura,Nobuyuki Arima. Is triple negative a prognostic factor in breast cancer [ J ] Breast Cancer, 2008,15:303 - 308.
-
8Tiwary R, Yu W, Sanders BG, Kline K, et al. ot - TEA cooperates with chemotherapeutic agents to induce ap- optosis of p53 mutant, triple - negative human breast cancer cells via activating p73 [ J ]. Breast Cancer, 2011,13 ( 1 ) :3721 - 3723.
-
9Moriya T, Kanomata N, KozuKa Y, et al. Moleaular morphological approach to the pathological study of development and advancement of human breast cancer [J]. Med Morphol,2010,43(2) :67.
-
10Chen J, Solomides C, Simpkins H, et al. Sensitization of mesothelioma cells to platinum - based chemother- apy by GSTπ knockdown [ J ]. Biochem - Biophys Commun,2014,447 ( 1 ) :77 - 82.
引证文献3
-
1师卫华,张艳.三阴性乳腺癌临床病理特征及多种相关蛋白表达的意义[J].宁夏医科大学学报,2015,37(2):181-184. 被引量:8
-
2张涛,梅亚男.Ki67、p53和PTEN在乳腺癌中的表达及临床意义[J].中国妇幼保健,2017,32(13):2862-2865. 被引量:9
-
3邹绮嫦,周泳健,甄逸.三阴乳腺癌AR及ki67的表达与预后[J].医学食疗与健康,2021,19(18):160-161.
二级引证文献17
-
1姜鸿南,李晓君,王伟.三阴乳腺癌组织中PTEN、p53和BAG-1的表达及临床意义[J].中国妇幼保健,2016,31(10):2198-2200. 被引量:4
-
2蒋丽,张建平.三阴性乳腺癌中p53和Ki67的表达情况及临床意义[J].河北医药,2017,39(8):1165-1167. 被引量:7
-
3冯燕,杨畅,延文,江涛.miR-185通过靶向BRCA1抑制三阴乳腺癌细胞的增殖与侵袭[J].中国老年学杂志,2017,37(21):5257-5260. 被引量:3
-
4魏林萍.P53和Ki67在胃癌组织中的表达及与治疗效果的相关性分析[J].中国实用医刊,2018,45(8):22-25. 被引量:1
-
5韩奇,韩兴荣.P53、Ki67、C-erbB-2在乳腺癌中的表达特征及与临床病理的相关性分析[J].浙江创伤外科,2018,23(2):224-225. 被引量:1
-
6沈恩超,黄中晶,赵志泓.三阴性乳腺癌中P53和Ki67表达情况的相关研究[J].江西医药,2018,53(7):680-682. 被引量:5
-
7何欣,刘凤磊,李晓琴,刘玮,罗雁,康雅琼.三阴性乳腺癌组织中P53、Ki-67表达与临床病理特征的相关研究[J].甘肃医药,2018,37(2):97-99. 被引量:1
-
8任丽影,佀凤侠,郝玲玲,邹爽.乳腺癌组织突变型p53和抑癌基因PTEN表达及其临床意义的研究[J].临床医药文献电子杂志,2019,6(24):95-95.
-
9刘庆伟.老年女性乳腺癌临床病理特征、治疗方式及预后的临床研究[J].牡丹江医学院学报,2019,40(3):70-73. 被引量:3
-
10王建君,徐小艳,冯智坤,杨金花.乳腺癌中PTEN和Basigin1蛋白的表达与其临床病理学特征的关系[J].中国普外基础与临床杂志,2020,27(7):825-830. 被引量:4
-
1王若曦,王水.乳腺癌ER、PR及HER-2在原发灶和转移灶之间表达关系的研究进展[J].江苏医药,2013,39(8):958-961. 被引量:11
-
2高海燕,朱玉兰,孙立,杨梅.三阴性和非三阴性乳腺癌中Ki67表达水平差异及机制研究[J].实用医学杂志,2014,30(2):333-334. 被引量:1
-
3崔猛胜,何招才,高玉娟,马雪平,王武.70岁及以上乳腺癌患者临床特点分析[J].中华老年医学杂志,2012,31(8):707-708. 被引量:4
-
4张学光,邰智慧,吉子炎,刘丽.HER-2在乳腺癌组织中的表达及其与血管生成的关系[J].山东医药,2008,48(17):82-83. 被引量:4
-
5李晓旭,王玉兰,薛剑侠,韩利强,郭敏红,郝美峰,靳晓乐,任艳珍,索玉平.尿液人附睾蛋白4在卵巢癌患者中的表达[J].山西医药杂志,2016,45(14):1630-1631. 被引量:1
-
6王树生,刘学敏,顾瑞香.70例乳腺癌组织中ER、PR、Her-2的表达及其意义[J].中国肿瘤外科杂志,2010,2(6):365-367.
-
7林青凤,茅卫东,刘少平,林峰,吕叶.紫杉醇+顺铂联合参一胶囊治疗晚期三阴性乳腺癌临床观察[J].现代中西医结合杂志,2011,20(30):3830-3831. 被引量:9
-
8王博,王敏,李俊海.VEGF在三阴性乳腺癌中的表达以及作为治疗靶点的研究进展[J].当代医学,2017,23(14):196-198. 被引量:6
-
9葛宇,朱家胜.人表皮生长因子受体2与血管内皮生长因子在结肠癌中的研究进展[J].沈阳医学院学报,2016,18(3):187-190. 被引量:4
-
10黄艳.HER2与乳腺癌对辅助化疗的反应相关[J].中国处方药,2006(7):75-75.